Organization Disclosures
PDF Print E-mail

Click here to view individual disclosures

Accelerated Cure
2009
Events - $300,019
Individual Giving - $698,523
Pharmaceutical Support - $124,125 (individual support listed as follows)
  • Biogen Idec - $60,000
  • EMD Serono - $40,000
  • Genentech - $10,050
  • Teva Neuroscience - $10,000
  • Pfizer - $4,075
  • Other Corporate/Foundation Support - $3,910,191
Total - $5,032,858
American Academy of Neurology

2010
Below is a breakdown of industry contribution towards the consolidated revenue of the Academy (American Academy of Neurology, American Academy of Neurology Institute, American Academy of Neurology Foundation, AAN Enterprises, Inc.). Industry includes for-profit entities that develop, produce, market, or distribute drugs, devices, services or therapies used to diagnose, treat, monitor, manage, and alleviate health conditions (e.g., pharmaceutical and medical device/software manufacturers and other for-profit health services/product providers). Industry does not include non-profit entities, entities outside of the healthcare sector, or entities through which physicians provide clinical services directly to patients (e.g., hospitals, medical centers, publishers, foundations, recruiters, insurance providers).

2010 Industry Contribution
  • Total Industry-related Revenue: $5,482,769
  • Percentage of Total Academy Revenue: 17%*
  • Educational Grants: $857,416
  • Sponsorship: $1,027,800
  • Charitable Contributions (Foundation): $83,000
  • Corporate Roundtable Membership Dues (Foundation): $690,000
  • Exhibit Space: $2,053,500
  • Advertising: $771,053
  • Companies Contributing over $100,000 in 2010:
    • Biogen Idec
    • TEVA Neuroscience, Inc.
    • Pfizer Inc.
    • Allergan, Inc.
    • EMD Serono, Inc.
    • UCB, Inc.
    • Acorda Therapeutics, Inc.
    • Novartis Pharmaceuticals
    • Bayer HealthCare Pharmaceuticals
    • Lilly USA, LLC
    • Sunovion Pharmaceuticals Inc. (formerly Sepracor)
    • Merz Pharmaceuticals, LLC
    • Forest Pharmaceuticals, Inc.
    • Lundbeck Inc.
*Based on forecasted amounts. 2010 audit not yet complete.

2009
Below is a breakdown of industry contribution towards the consolidated revenue of the Academy (American Academy of Neurology, American Academy of Neurology Institute, American Academy of Neurology Foundation, AAN Enterprises, Inc.). Industry includes for-profit entities that develop, produce, market, or distribute drugs, devices, services or therapies used to diagnose, treat, monitor, manage, and alleviate health conditions (e.g., pharmaceutical and medical device/software manufacturers and other for-profit health services/product providers). Industry does not include non-profit entities, entities outside of the healthcare sector, or entities through which physicians provide clinical services directly to patients (e.g., hospitals, medical centers, publishers, foundations, recruiters, insurance providers).

2009 Industry Contribution
  • Total Industry-related Revenue: $5,538,907
  • Percentage of Total Academy Revenue: 18%
  • Educational Grants: $944,483
  • Sponsorship: $1,231,230
  • Charitable Contributions (Foundation): $ -
  • Corporate Roundtable Membership Dues (Foundation): $450,000
  • Exhibit Space: $2,426,700
  • Advertising: $486,494
  • Companies Contributing over $100,000 in 2009:
    • Biogen Idec
    • TEVA Neuroscience, Inc.
    • UCB, Inc.
    • Allergan, Inc.
    • Pfizer Inc.
    • Bayer HealthCare Pharmaceuticals
    • Acorda Therapeutics, Inc.
    • EMD Serono, Inc.
    • Lilly USA, LLC
    • Lundbeck Inc.
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Ortho-McNeil Neurologics, Inc.
    • Cephalon, Inc.
    • Forest Pharmaceuticals, Inc.
    • Questcor Pharmaceuticals, Inc.
    • Merck
Americas Committee for Treatment and Research in Multiple Sclerosis

ACTRIMS is a community of leaders dedicated to treatment and research in multiple sclerosis, dissemination of knowledge and education, and collaboration among disciplines. It also seeks to foster clinical and research talent among young researchers. ACTRIMS is dedicated to providing leadership in the field of multiple sclerosis and other demyelinating diseases.

ACTRIMS is a board-directed, non-membership organization. Founded in 1995 ACTRIMS was formally incorporated in 2009 and was recognized by the IRS as a tax exempt organization under section 501(c)(3) of the Internal Revenue Code. The present principle activity of ACTRIMS is to provide an annual educational meeting for the presentation, discussion and debate of current topics in MS clinical and basic research. Participants include clinicians, clinical scientists, and basic researchers. In select years since 1999, ACTRIMS has held joint meetings with its European counterpart, ECTRIMS. Sources of revenue include registration fees, sponsorship, exhibit hall fees and advertising.

2010
ACTRIMS received educational grants in support of its annual meeting. Contributors included the following:
  • Advir - $5,000
  • Genzyme - $5,000
  • Society of Canada - $14,625
  • Teva Neuroscience - $25,000
Can Do Multiple Sclerosis
Can Do Multiple Sclerosis is an innovative provider of lifestyle empowerment programs for people with MS and their support partners who want to overcome the challenges of their disease and learn what is possible with MS. Can Do MS envisions a world in which all people impacted by MS maximize their potential, improving their quality of life. It is our mission to lead the way with comprehensive programs that empower people and families living with MS to transform and improve their quality of life. Achieving our vision requires a diverse base of support. Our sources of support include the following:

Pharmaceutical Support: Pharmaceutical companies provide financial support for our lifestyle empowerment programs and patient and professional education. Total pharmaceutical support is 48% ($727,076 in 2013) of our total annual revenue.

Individual Giving: Generous individual donors also provide funding for our lifestyle empowerment programs. Donations at all giving levels contribute approximately 27% ($412,461 in 2013) to our annual revenue.

Foundation Support: Foundation support is 17% ($255,275 in 2013) of our annual revenue. Many local and national foundations also support our programs and assist in our bringing them to various areas around the country.

Corporate support of approximately 10% ($152,178 in 2013) added to our total revenue. Corporations across the country support our mission through direct financial support, cause-related partnerships, and in-kind goods and services.

Special Events: Can Do MS benefits from special events held throughout the year which raise funds needed to support our mission. The major fundraising events in 2013 were the Vertical Express for Can Do MS event series (at Crystal Mountain, WA; Schweitzer Mountain, ID; and Squaw Valley, CA), the Alpen Wine Festival (Squaw Valley, CA), the Cut N Slice Golf Tournament (Beaver Creek, CO), Can Do Day (Eagle County, CO), and the Annual Autumn Benefit (New York City).

Additionally, Can Do MS benefits from events conducted by supporters of our mission all over the country. These events include an endurance run, fundraising dinners, a golf event, among others. Approximately 41% ($621,700) of the total 2013 revenue of Can Do MS was raised by special events.
Consortium of Multiple Sclerosis Centers
2010

The Consortium of Multiple Sclerosis Centers is the grateful recipient of grants and other support from: Acorda Therapeutics, Inc., Allergan, Inc., Bayer HealthCare Pharmaceuticals, Inc., BiogenIdec, EMD Serono, Novartis Pharmaceuticals, Inc., and TEVA Pharmaceuticals U.S.A.
International Organization of Multiple Sclerosis Nurses
2010

The International Organization of Multiple Sclerosis Nurses is the grateful recipient of grants and other support from: Acorda Therapeutics, Inc., Bayer HealthCare Pharmaceuticals, Inc., BiogenIdec and TEVA Pharmaceuticals U.S.A.
Multiple Sclerosis Association of America
2013
Pharmaceutical Industry Supporters:
Acorda Therapeutics Inc. $139,300
Allergan, Inc. $111,489
Bayer Healthcare Pharmaceuticals $60,940
Biogen Idec $234,614
EMD Serono, Inc. and Pfizer, Inc. $449,820
Genentech, Inc. $15,000
Genzyme $395,426
Medtronic Foundation $45,500
Novartis Pharmaceuticals Corporation $330,495
Questcor Pharmaceuticals, Inc. $340,740
Teva Pharmaceuticals $384,046

2010
Total Pharmaceutical Revenue: $2.74 M
Percentage of Total Revenue (25%)
Sponsorships 1.6 M
Advertising 0.03 M
Grants 0.9 M
Total Contribution w/out MS product in the Market in 2010: 0.2 M
Total Contribution with MS product in the Market in 2010:
Bayer 0.11 M
Biogen 0.03 M
Genentech 0.13 M
Acorda 0.11 M
Serono 1.20 M
Teva 0.95 M
The Multiple Sclerosis Foundation
2010
The Multiple Sclerosis Foundation is a service-based, publicly funded 501(c)3 organization that strives to provide a comprehensive approach to helping people with MS maintain their health and well-being. We offer programming and support to keep them self-sufficient and their homes safe, while our educational programs heighten public awareness and promote understanding about the disease.

Our resources assist people who have MS, their families and caregivers, regional support groups, and healthcare professionals. Access to our programs and services is available through our interactive web site or our national, toll-free helpline staffed by caring caseworkers and peer counselors. Our priority is to serve with empathy, resourcefulness and responsibility.

All MSF services, as well as information, literature and subscriptions to our publications are provided free of charge. The MSF neither sells memberships nor requires participation in fund-raising activities by individuals or support groups.

To achieve this mission, the MSF receives support from the following sources:

*Individual giving: 83.1 percent. The generosity of individual donors provides the majority of our annual revenue.

*Pharmaceutical grants (educational and charitable): 8.7 percent. Grants have been received from Teva Neuroscience, Biogen Idec, EMD Serono, Acorda Therapeutics, Novartis, Bayer and Genentech.

*Other: 8.2 percent. This segment includes funds from businesses and corporations outside of the pharmaceutical industry as well as matching gifts and special events.

Additionally, the MSF continues to advance partnerships and develop initiatives with other organizations, educational institutions, MS Centers, healthcare professionals, and individuals who share our commitment to learning more about MS as well as improving the quality of life for those who live with the disease.
National Multiple Sclerosis Society
2009
We all share a vision for the future: A world free of multiple sclerosis. Achieving our mission, and ultimately ending MS forever, requires reliance on a broad base of support. Each year, hundreds of thousands of people give generously to the Society. In fact, the large majority of our funds come from people making contributions of less than $100. Our sources of support include the following:

Special Events: The Society offers hundreds of special events throughout the year to engage participants and fundraisers critical to supporting the mission. Approximately 65% ($135 million in 2009) of the Society's total annual revenue is raised through special events, including Bike MS and Walk MS events.

Individual Giving: Generous individual donors provide a substantial source of funding toward the mission. Donations at all giving levels contribute approximately 31% ($65 million in 2009) of the Society's total annual revenue.

Pharmaceutical Support: Pharmaceutical organizations provide financial support for client programs and education, professional and clinical development, and event support. In total, pharmaceutical support is 5% of the Society's total annual revenue.
  • Total Pharmaceutical Revenue in 2009: $10.4 million
    • Sponsorship: $3.8 million
    • Grants: $2.5 million
    • Advertising: $1 million
    • Total contribution by companies without an MS product on market in 2009: $3.1 million
    • Total contribution by company with an MS product on market in 2009:
      • Bayer: $697,662
      • Biogen Idec: $1,096,987
      • EMD Serono/Pfizer: $2,853,514
      • Novartis: $179,000
      • Teva: $1,542,699
Corporate Support: Corporations across the country support the mission through direct financial support, cause-related or value-add partnerships, and even through significant pro-bono services. Direct corporate support of approximately $2 million in 2009, rounds out the remainder of the Society's total annual revenue.
United Spinal Association
2010 United Spinal Association is a 501(c)(3) membership organization that is dedicated to improving the lives of individuals with spinal cord injuries and disorders. Since 1946, United Spinal Association has encouraged its members and the larger community of all people with mobility disabilities to maximize their community integration and has worked to eliminate barriers that impede that goal. Through robust advocacy, communications, education and direct service programs, United Spinal removes physical, legislative, medical and attitudinal barriers that impede our members' independence and or quality of life.

Access to our programs and services is available online, in print, through our toll-free helpline and through a variety of seminars and events held throughout the year.

To achieve our mission, United Spinal Association receives support from the following sources:
Individual Giving $12.2M (68.9%)
Bequests $ 0.3M (1.7%)
Programs and Services $ 1.8M (10.2%)
Donated Services and Facilities $ 3.2M (18.1%)
Pharmaceutical Revenue* >$ 0.05M (<0.2%)
Other $ 0.2M (1.1%)
Total Contributions: $17.7M

*- United Spinal Association participated in Allergan's Open Arms Campaign, promoting Botox© for use with patients with Upper Limb Spasticity.
VA Centers of Excellence – East and West
2010
The Veterans Administration and the MS Centers of Excellence are prohibited from receiving funds or other forms of support from industry or any entity doing business with the US federal government.